WO2003037930A8 - Novel human n-methyl-d-asparatate (nmda) glutamate receptor polypeptide and gene encoding the same - Google Patents

Novel human n-methyl-d-asparatate (nmda) glutamate receptor polypeptide and gene encoding the same

Info

Publication number
WO2003037930A8
WO2003037930A8 PCT/JP2002/011207 JP0211207W WO03037930A8 WO 2003037930 A8 WO2003037930 A8 WO 2003037930A8 JP 0211207 W JP0211207 W JP 0211207W WO 03037930 A8 WO03037930 A8 WO 03037930A8
Authority
WO
WIPO (PCT)
Prior art keywords
nr3a
gene encoding
glutamate receptor
nmda
human
Prior art date
Application number
PCT/JP2002/011207
Other languages
French (fr)
Japanese (ja)
Other versions
WO2003037930A1 (en
Inventor
Hiroshi Mori
Osamu Ohara
Takahiro Nagase
Reiko Kikuno
Keiji Yamagami
Yoshitaka Ohashi
Original Assignee
Kazusa Dna Res Inst Foundation
Hiroshi Mori
Mitsubishi Pharma Corp
Osamu Ohara
Takahiro Nagase
Reiko Kikuno
Keiji Yamagami
Yoshitaka Ohashi
Iritani Shuji
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kazusa Dna Res Inst Foundation, Hiroshi Mori, Mitsubishi Pharma Corp, Osamu Ohara, Takahiro Nagase, Reiko Kikuno, Keiji Yamagami, Yoshitaka Ohashi, Iritani Shuji filed Critical Kazusa Dna Res Inst Foundation
Priority to JP2003540211A priority Critical patent/JPWO2003037930A1/en
Publication of WO2003037930A1 publication Critical patent/WO2003037930A1/en
Publication of WO2003037930A8 publication Critical patent/WO2003037930A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)

Abstract

It is intended to find out a novel substance relating to human NMDA glutamate receptor subunit 3A (NR3A). A novel cDNA originating in human brain is isolated and the full base sequence thereof is analyzed. Then this base sequence is translated into an amino acid sequence followed by homology searching. As a result, it is found out that this sequence has a 93% homology with rat NR3A and thus identified as human NR3A. Further, it is confirmed that a gene encoding NR3A is significantly increased in the brain of patients with schizophrenia. Thus, it is concluded that NR3A is a substance relating to the pathology of schizophrenia.
PCT/JP2002/011207 2001-10-29 2002-10-29 Novel human n-methyl-d-asparatate (nmda) glutamate receptor polypeptide and gene encoding the same WO2003037930A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003540211A JPWO2003037930A1 (en) 2001-10-29 2002-10-29 Novel human N-methyl-D-aspartate (NMDA) glutamate receptor polypeptide and gene encoding the same

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2001-331007 2001-10-29
JP2001331007 2001-10-29
JP2001-333258 2001-10-30
JP2001333258 2001-10-30
JP2001345262 2001-11-09
JP2001-345262 2001-11-09

Publications (2)

Publication Number Publication Date
WO2003037930A1 WO2003037930A1 (en) 2003-05-08
WO2003037930A8 true WO2003037930A8 (en) 2004-06-03

Family

ID=27347747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/011207 WO2003037930A1 (en) 2001-10-29 2002-10-29 Novel human n-methyl-d-asparatate (nmda) glutamate receptor polypeptide and gene encoding the same

Country Status (2)

Country Link
JP (1) JPWO2003037930A1 (en)
WO (1) WO2003037930A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004507202A (en) * 1999-03-31 2004-03-11 キュラジェン　コーポレイション Nucleic acid containing an open reading frame encoding a polypeptide; "ORFX"
US20040115761A1 (en) * 1999-12-14 2004-06-17 Spaderna Steven Kurt Polypeptides and nucleic acids encoding same
US20020034778A1 (en) * 2000-04-27 2002-03-21 Pe Corporation (Ny) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
EP1320600A1 (en) * 2000-08-03 2003-06-25 Incyte Genomics, Inc. Transporters and ion channels
WO2002024743A2 (en) * 2000-09-19 2002-03-28 Millennium Pharmaceuticals, Inc. 55063, a human nmda family member and uses thereof
AU2002227929A1 (en) * 2000-11-17 2002-05-27 Bayer Aktiengesellschaft Regulation of human nmda receptor

Also Published As

Publication number Publication date
JPWO2003037930A1 (en) 2005-02-17
WO2003037930A1 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
BR0207325A (en) Therapeutic methods for diseases associated with decreased aop-1 or aop-1 gene expression
WO2003020932A1 (en) Novel secretory proteins and dna thereof
EP2298355A3 (en) Albumin fusion proteins
IS8622A (en) Method of Preparation of Polypeptide Preparations Using Purified Hydrochloric Acid
IL195338A (en) Antibody comprising an fc variant comprising d or e amino acid substitution at position 239 and pharmaceutical composition and use thereof
AU5608000A (en) 22025, a novel human cyclic nucleotide phosphodiesterase
HK1079549A1 (en) Muteins of placental growth factor type 1, preparation method and application thereof
KR980002066A (en) Mutant human growth hormone and uses thereof
WO2004080957A3 (en) Use of adnf polypeptides for treating anxiety and depression
WO2003037930A1 (en) Novel human n-methyl-d-asparatate (nmda) glutamate receptor polypeptide and gene encoding the same
WO2003075944A3 (en) Interferon beta-like molecules for treatment of stroke
AUPR775401A0 (en) Novel Epitopes and Uses Thereof
AU2001232275A1 (en) Novel collagen-like protein clac, precursor thereof and genes encoding the same
IL162133A0 (en) Method of increasing protein expression, proteins and polynucleotides
WO2003082897A3 (en) Synthetic active peptide fragments
WO2001090139A3 (en) A ligand for enhancing oral and cns delivery of biological agents
WO2004113511A3 (en) Cell line and uses thereof
WO2001090141A3 (en) Gb1c isoform and nucleotides
WO2003089461A3 (en) Purified dutpase from helicobacter pylori
WO2002016435A3 (en) Human 7tm proteins and polynucleotides encoding the same
WO2001094417A3 (en) Novel human seven transmembrane proteins and polynucleotides encoding the same
WO2002061083A1 (en) Novel g protein-coupled receptor protein and dna thereof
WO2002036633A3 (en) Human 7tm proteins and polynucleotides encoding the same
WO2004000204A8 (en) Labelled somatostatin analogs backbone cyclized through metal complexation
WO2001064887A3 (en) 32705, 23224, 27423, 32700, 32712, novel human g-proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003540211

Country of ref document: JP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 19/2003 UNDER (72, 75) DELETE "IRITANI, SHUJI [JP/JP]; ROOM 110, ABITASHION-ROKAKOUEN, 11-25, KASUYA 2-CHOME, SETAGAYA-KU, TOKYO 157-0063"; UNDER (71) ADD "IRITANI, SHUJI [JP/JP]; ROOM 110, ABITASHION-ROKAKOUEN, 11-25, KASUYA 2-CHOME, SETAGAYA-KU, TOKYO 157-0063"

122 Ep: pct application non-entry in european phase